The pharmaceutical giant recently cut its dividend, but it still pays a better yield than most in the industry.
News & Analysis: GlaxoSmithKline
These stocks can diversify your portfolio, minimize your risk, and provide you with great long-term returns.
Both pharmaceutical giants are developing coronavirus vaccines. Which is a better buy?
Simply put, adjuvants make vaccines work better; this one could be useful in conjunction with a number of SARS-CoV-2 vaccine candidates.
The test could diagnose individuals in 20 minutes without the need for lab equipment.
Both companies are weathering the bear market well as they lead the race to develop the coronavirus vaccine. But which is the better buy?
A study showed that cabotegravir works better than the current pre-exposure prophylaxis treatment, but there may be issues with getting it approved.
These payouts are in good shape and there's plenty of reason to be bullish on these stocks.
Size may matter in the long run.
Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.